Thyroid hormone regulation of lipid metabolism affects a wide range of interrelated health parameters, from levels of cholesterol and triglycerides in the blood to the pathological buildup of fat in the liver. Selective thyroid hormone receptor beta (THR)-β activation in the liver is an appealing target for therapeutics intended to address dysregulation of lipid metabolism.
Madrigal is advancing MGL-3196 for the treatment of NASH and familial hypercholesterolemias. The Company has multiple clinical trial initiations and data readouts for MGL-3196 planned through 2017 into 2018, including the results of Phase 2 trials in NASH and FH patients. Learn More